Literature DB >> 7649718

Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine.

F Fernandez1, J K Levy, H R Samley, F J Pirozzolo, D Lachar, J Crowley, S Adams, B Ross, P Ruiz.   

Abstract

This report is a randomized, double-blind, comparative trial of desipramine with the psychomotor stimulant methylphenidate. Twenty HIV antibody-positive patients with depressive symptoms were randomly assigned to either drug. After individual dose titration, the mean daily dose of desipramine was 150 mg. and methylphenidate 30 mg. daily. The differences in responses between desipramine and methylphenidate were not statistically significant on various measures of depression. The antidepressant effect of methylphenidate did not occur any faster than that of desipramine. Both significantly reduced depressive and anxious symptomatology over the blinded portion of the treatments. Thus, methylphenidate relieves depressive symptomatology with efficacy similar to that of desipramine, offering an alternative to patients who are unable to tolerate standard tricyclic antidepressant therapy. The dopaminergic effects of methylphenidate are likely to mediate its antidepressant effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649718     DOI: 10.2190/16FH-9ECT-Y280-VV45

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  16 in total

Review 1.  Drug treatment of depression in HIV-positive patients : safety considerations.

Authors:  Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Identifying and managing depression in the medical patient.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

4.  HIV Prevention and Intervention in Psychiatrically Ill Youths.

Authors:  Geri R Donenberg; Maryland Pao
Journal:  Contemp Psychiatry (Hagerstown Md)       Date:  2004-01

Review 5.  [Antidepressants for treatment of depression in palliative patients : a systematic literature review].

Authors:  M Ujeyl; B Müller-Oerlinghausen
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 6.  Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action.

Authors:  Erica Weber; Kaitlin Blackstone; Steven Paul Woods
Journal:  Neuropsychol Rev       Date:  2013-02-16       Impact factor: 7.444

Review 7.  Neuropsychiatric manifestations of HIV infection and AIDS.

Authors:  Benoit Dubé; Tami Benton; Dean G Cruess; Dwight L Evans
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

8.  Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.

Authors:  Bruno Gagnon; Graeme Low; Gil Schreier
Journal:  J Psychiatry Neurosci       Date:  2005-03       Impact factor: 6.186

Review 9.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

10.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.